A Double-Blind Trial Platform Based on Distributed Ledger Technology

In the pharmaceutical research and development process, the third phase of clinical trials involves double-blind trials to mitigate the influence of human subjective awareness on the experimental results and ensure the efficacy and safety of drugs or vaccines. However, conventional double-blind tria...

Full description

Saved in:
Bibliographic Details
Published in:Electronics (Basel) 2024-01, Vol.13 (1), p.132
Main Authors: Yeh, Yi-Hong, Hsueh, Sheng-Chun, Liang, Tyng-Yeu
Format: Article
Language:English
Subjects:
Access control
Blockchain
Clinical trials
Contracts
Data loss
Data security
Distributed ledger
Double-blind studies
Drugs
Electronic data processing
Experiments
Methods
Pharmaceutical industry
Placebo effect
Public participation
R&D
Research & development
Researchers
Technology application
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the pharmaceutical research and development process, the third phase of clinical trials involves double-blind trials to mitigate the influence of human subjective awareness on the experimental results and ensure the efficacy and safety of drugs or vaccines. However, conventional double-blind trials are often overseen by a single institution responsible for the entire trial process. Researchers centrally manage data, introducing risks of data loss and tampering. Furthermore, since researchers have full access to all experimental data, there is a potential for premature unblinding and leakage of results to specific individuals, giving rise to bias and conflicts of interest. To address these problems, this paper proposes a distributed-ledger-based double-blind trial platform called “BlindBox”. This platform leverages the immutability and decentralization of distributed ledgers to enhance the security of experimental data. On the other hand, the platform employs smart contracts to restrict personnel’s access to experimental data, coupled with RFID technology to encode and shuffle the experimental drugs discreetly. This ensures that no one can ascertain the pairing between test subjects and drug groups, preventing collusion and result manipulation. When the trial period concludes, smart contracts automatically unblind the results and publish them on the IOTA platform. By utilizing IOTA’s zero-value transactions, the platform reduces the cost of repeated data access and ensures information openness and transparency. This approach prevents deliberate premature unblinding or insider trading stemming from monopolized information. The platform proposed in this study is expected to enhance the credibility and accuracy of double-blind trials while promoting the willingness and convenience of public participation in experiments.
ISSN:2079-9292
2079-9292
DOI:10.3390/electronics13010132